

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING**Product Identifier****Material Name:** Diclofenac Sodium and Misoprostol Tablets (Greenstone LLC)**Trade Name:** Not applicable**Chemical Family:** Mixture**Relevant Identified Uses of the Substance or Mixture and Uses Advised Against****Intended Use:** Pharmaceutical product used as non-steroidal, anti-inflammatory drug (nsaid)**Details of the Supplier of the Safety Data Sheet**Greenstone LLC
100 Route 206 North
Peapack, NJ 07977
800-435-7095**Emergency telephone number:**
CHEMTREC (24 hours): 1-800-424-9300**2. HAZARDS IDENTIFICATION****Classification of the Substance or Mixture****GHS - Classification**Acute Oral Toxicity: Category 4
Skin Corrosion/Irritation: Category 2
Serious Eye Damage/Eye Irritation: Category 2
Reproductive Toxicity: Category 1B**EU Classification:**EU Indication of danger: Harmful
Toxic to Reproduction: Category 2**EU Risk Phrases:**R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.**Label Elements****Signal Word:** Danger**Hazard Statements:**
H315 - Causes skin irritation
H319 - Causes serious eye irritation
H302 - Harmful if swallowed
H360D - May damage the unborn child**Other Hazards**

No data available

SAFETY DATA SHEET

Material Name: Diclofenac Sodium and Misoprostol Tablets
(Greenstone LLC)
Revision date: 05-May-2015

Page 2 of 11

Version: 2.0

Australian Hazard Classification (NOHSC): Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Diclofenac Sodium	15307-79-6	239-346-4	T; R25; Xi,R36/38; Repr. Cat.2, R61; R52/53	Skin Irrit 2 (H315) Eye Irrit.2A (H319) Acute Tox.3 (H301) Repr.1B (H360D) Aquatic Acute 3 (H402) Aquatic Chronic 3 (H412)	8-15
Misoprostol	59122-46-2	Not Listed	T;R25 Repr.Cat.1;R60-61	Acute Tox. 3 (H301) Repr.1A (H360FD)	<1.0

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Methacrylic acid copolymer	25086-15-1	Not Listed	Not Listed	Not Listed	*
Triethyl Citrate	77-93-0	201-070-7	Not Listed	Not Listed	*

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

- Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
- Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
- Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
- Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

SAFETY DATA SHEET

Material Name: Diclofenac Sodium and Misoprostol Tablets
(Greenstone LLC)
Revision date: 05-May-2015

Page 3 of 11

Version: 2.0

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

SAFETY DATA SHEET

Material Name: Diclofenac Sodium and Misoprostol Tablets
(Greenstone LLC)
Revision date: 05-May-2015

Page 4 of 11

Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Misoprostol

Manufacturer OEL: 0.7ug/m³

Diclofenac Sodium

Manufacturer OEB: OEB2 (control exposure to the range of >100ug/m³ to < 1000ug/m³)

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:

Tablets

Color:

White

Odor:

No data available.

Odor Threshold:

No data available.

Molecular Formula:

Mixture

Molecular Weight:

Mixture

Solvent Solubility:

No data available

Water Solubility:

No data available

pH:

No data available.

Melting/Freezing Point (°C):

No data available

Boiling Point (°C):

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Povidone

No data available

Corn Starch

No data available

Crospovidone

No data available

Talc (non-asbestiform)

No data available

Lactose Monohydrate

No data available

Silicon dioxide, colloidal NF

No data available

Magnesium stearate

No data available

SAFETY DATA SHEET

Material Name: Diclofenac Sodium and Misoprostol Tablets
(Greenstone LLC)
Revision date: 05-May-2015

Page 5 of 11

Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Hydrogenated castor oil

No data available

Microcrystalline cellulose

No data available

Hydroxypropyl methylcellulose

No data available

Triethyl Citrate

No data available

Methacrylic acid copolymer

No data available

Diclofenac Sodium

Predicted Log P 4.51

Misoprostol

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable at normal conditions

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May cause eye irritation May cause skin irritation. (based on components)

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on blood spleen reproductive system gastrointestinal system Animal studies indicate that this material may cause adverse effects on the the developing fetus.

SAFETY DATA SHEET

Material Name: Diclofenac Sodium and Misoprostol Tablets
(Greenstone LLC)
Revision date: 05-May-2015

Page 6 of 11

Version: 2.0

11. TOXICOLOGICAL INFORMATION

Known Clinical Effects: Clinical use has caused effects on the gastrointestinal system, including abdominal pain, nausea, vomiting, diarrhea, constipation, peptic ulcer, acid reflux, and gastrointestinal bleeding. Clinical use has resulted in liver effects. Symptoms may include jaundice, liver function test abnormalities, and hepatitis. Clinical use has caused effects on the nervous system, including drowsiness, anxiety, dizziness, visual disturbances. Serious allergic reactions, including anaphylaxis, have been reported. Clinical use of this drug has caused decreased red blood cell count (anemia), effects on blood forming organs. Drugs of this class may cause menstrual irregularities, cramps, pain, postmenopausal menstrual bleeding, miscarriage, uterine rupture, bleeding and death. Miscarriages have been seen in pregnant women taking this drug. Clinical use has caused effects on the cardiovascular system, including heart attack (myocardial infarction), stroke.

Acute Toxicity: (Species, Route, End Point, Dose)

Povidone

Rat Oral LD50 100 g/kg

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Lactose Monohydrate

Rat Oral LD 50 29700 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg

Rat Inhalation LC50 > 2000 mg/m³

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg

Rabbit Dermal LD50 > 2000 mg/kg

Hydroxypropyl methylcellulose

Rat Oral LD50 > 10,000 mg/kg

Diclofenac Sodium

Rat Oral LD 50 53-77 mg/kg

Misoprostol

Rat Oral LD 50 81 mg/kg

Rat Inhalation LC 50 > 1.43mg/L

Mouse Oral LD 50 27mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating

Eye Irritation Rabbit Non-irritating

Diclofenac Sodium

Skin Irritation Positive

SAFETY DATA SHEET

Material Name: Diclofenac Sodium and Misoprostol Tablets
(Greenstone LLC)
Revision date: 05-May-2015

Page 7 of 11

Version: 2.0

11. TOXICOLOGICAL INFORMATION

Eye Irritation Positive

Misoprostol

Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Diclofenac Sodium

30 Day(s) Rat Oral 14 mg/kg LOEL None identified
5 Week(s) Mouse Oral 9 mg/kg LOEL Lungs, Spleen
26 Week(s) Rat Oral 50 mg/kg LOEL Blood, Gastrointestinal system

Misoprostol

4 Week(s) Dog Intravenous 10 µg/kg/day LOEL Liver, Blood
13 Week(s) Rat Oral 120 µg/kg/day LOEL Gastrointestinal system
13 Week(s) Dog Oral 30 µg/kg/day LOEL Gastrointestinal system
1 Year(s) Rat Oral 160 µg/kg/day LOEL Gastrointestinal system
1 Year(s) Dog Oral 30 µg/kg/day LOEL Gastrointestinal system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Diclofenac Sodium

Embryo / Fetal Development Rat Oral 24 mg/kg LOEL Maternal toxicity, Fetotoxicity
Embryo / Fetal Development Rat 1 mg/kg LOEL Developmental toxicity
Embryo / Fetal Development Rat No route specified 20 mg/kg/day NOEL Not Teratogenic
Embryo / Fetal Development Rabbit No route specified 10 mg/kg/day NOEL Not Teratogenic

Misoprostol

Reproductive & Fertility Rat Oral 10 mg/kg/day LOEL Fertility
Embryo / Fetal Development Rabbit Oral 1 mg/kg/day LOEL Embryotoxicity
Embryo / Fetal Development Mouse Oral 30 mg/kg LOEL Embryotoxicity
Embryo / Fetal Development Rabbit Oral 1 mg/kg/day NOEL Not Teratogenic
Embryo / Fetal Development Rat Oral 10 mg/kg/day NOEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Lactose Monohydrate

In Vitro Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative

Diclofenac Sodium

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Misoprostol

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vitro Mouse Lymphoma Negative
Sister Chromatid Exchange Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Diclofenac Sodium

Not specified Rat Oral 2 mg/kg/day NOEL Not carcinogenic

SAFETY DATA SHEET

Material Name: Diclofenac Sodium and Misoprostol Tablets
(Greenstone LLC)
Revision date: 05-May-2015

Page 8 of 11

Version: 2.0

11. TOXICOLOGICAL INFORMATION

Misoprostol

21 Month(s)	Mouse	Oral	16 mg/kg/day	NOAEL	Not carcinogenic
24 Month(s)	Rat	Oral	2.4 mg/kg/day	NOAEL	Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Povidone

IARC: Group 3 (Not Classifiable)

Crospovidone

IARC: Group 3 (Not Classifiable)

Talc (non-asbestiform)

IARC: Group 3 (Not Classifiable)

Silicon dioxide, colloidal NF

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: May have harmful effects on the aquatic environment. Releases to the environment should be avoided. This formulation has not been tested as a whole, the following apply to component substance(s):

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Diclofenac Sodium

<i>Oncorhynchus mykiss</i> (Rainbow Trout)	EC-50	96 Hours	130.6 mg/L
<i>Daphnia magna</i> (Water Flea)	EC50	48 Hours	68 mg/L
<i>Skeletonema costatum</i> (Marine Diatom)	ErC50	48 Hours	42 mg/L
<i>Skeletonema costatum</i> (Marine Diatom)	EC-50	72 Hours	100 mg/L

Misoprostol

<i>Daphnia</i>	LC-50	48 Hours	> 932.5 mg/L
<i>Oncorhynchus mykiss</i> (Rainbow Trout)	LC-50	72 Hours	> 26.4 mg/L
<i>Skeletonema costatum</i> (Marine Diatom)	ErC50	72 Hours	> 104 mg/L
<i>Skeletonema costatum</i> (Marine Diatom)	NOEC		26.5 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Persistence and Degradability:

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Diclofenac Sodium

Ready 55% After 28 Day(s) Not Ready

Bio-accumulative Potential:

SAFETY DATA SHEET

Material Name: Diclofenac Sodium and Misoprostol Tablets
(Greenstone LLC)
Revision date: 05-May-2015

Page 9 of 11

Version: 2.0

Partition Coefficient: (Method, pH, Endpoint, Value)

Diclofenac Sodium

Predicted Log P 4.51

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 1, Subdivision B

Class D, Division 2, Subdivision A



Diclofenac Sodium

CERCLA/SARA 313 Emission reporting

Not Listed

California Proposition 65

Not Listed

Australia (AICS):

Present

EU EINECS/ELINCS List

239-346-4

Misoprostol

CERCLA/SARA 313 Emission reporting

Not Listed

SAFETY DATA SHEET

Material Name: Diclofenac Sodium and Misoprostol Tablets
(Greenstone LLC)
Revision date: 05-May-2015

Page 10 of 11

Version: 2.0

15. REGULATORY INFORMATION

California Proposition 65	developmental toxicity initial date 4/1/90
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

Methacrylic acid copolymer

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Triethyl Citrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-070-7

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.3; H301 - Toxic if swallowed
Skin corrosion/irritation-Cat.2; H315 - Causes skin irritation
Serious eye damage/eye irritation-Cat.2A; H319 - Causes serious eye irritation
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Hazardous to the aquatic environment, acute toxicity-Cat.3; H402 - Harmful to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.3; H412 - Harmful to aquatic life with long lasting effects
Reproductive toxicity-Cat.1A; H360FD - May damage fertility. May damage the unborn child.

T - Toxic
Xi - Irritant
Toxic to Reproduction: Category 2
Toxic to reproduction: Category 1

R25 - Toxic if swallowed.
R60 - May impair fertility.
R61 - May cause harm to the unborn child.
R36/38 - Irritating to eyes and skin.
R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 15 - Regulatory Information. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

Revision date: 05-May-2015

SAFETY DATA SHEET

**Material Name: Diclofenac Sodium and Misoprostol Tablets
(Greenstone LLC)**
Revision date: 05-May-2015

Page 11 of 11

Version: 2.0

Prepared by:

Product Stewardship Hazard Communication
Global Environment, Health, and Safety Operations

It is believed that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time

End of Safety Data Sheet